Monoclonal Antibody Pipeline Focused on Oncology

Dedicated to changing patients’ lives.

Learn More

Better Life Through Better Science

KaloBios is developing proprietary customized, targeted, first-in-class monoclonal antibodies designed to significantly improve the care of seriously ill patients with cancer.

Recent Corporate Highlights

  • Initiated Phase 2 expansion portion of clinical trial for KB004 in hematologic malignancies
  • Announced preliminary Phase 1 results in advanced hematologic malignancies with KB004 at ASH Annual Meeting

Read All

Latest News

August 10, 2015

KaloBios Reports Second Quarter Financial Results and Provides Clinical Update

July 29, 2015

KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia

July 29 2015

KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement

Ongoing Clinical Trials

Currently enrolling patients with myelofibrosis or myelodysplastic syndrome in Phase 2 expansion portion of Phase 1/2 clinical trial in hematologic malignancies.

You are now leaving this website. If you would like to continue, click Continue.